Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of a recombinant RSV vaccine in adults aged 60 years and older
CTR20253963Phase 3Active
- Sponsor
- Chengdu Huarenkang Biotechnology
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus disease (RSV), sponsored by Chengdu Huarenkang Biotechnology. Started Oct 2025; status: active.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20253963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253963.